Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-arm, Phase II Trial of Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Advanced Non-squamous Non-small Cell Lung Cancer After First-line Immunotherapy Progression

NCT05738317 is registered in ClinicalTrials.gov with Xiaorong Dong as lead sponsor.

NCT NCT05738317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05738317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-arm, Phase II Trial of Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Advanced Non-squamous Non-small Cell Lung Cancer After First-line Immunotherapy Progression
Lead sponsor
Xiaorong Dong
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2022
Completion date
December 1, 2024
Enrollment
45 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer